Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for JAPAF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for JAPAF and 80,000+ other tickers.
See exactly how JAPAF's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for JAPAF and 80,000+ other tickers.
Japan Tobacco Inc. (JTI) is a diversified global enterprise that manufactures and distributes tobacco products, pharmaceuticals, and various processed foods. Its operations are organized into four distinct divisions: Domestic Tobacco, International Tobacco, Pharmaceutical, and Processed Food. JTI's comprehensive tobacco portfolio includes traditional offerings like cigarettes, cigars, pipe tobacco, oral tobacco, waterpipe tobacco, kretek, and fine cut products, sold under prominent brands such as Winston, Camel, MEVIUS, and LD. Additionally, the company is a key player in the reduced-risk…
Japan Tobacco is rated BUY, trading at a 19% discount to Philip Morris despite similar forward EPS growth expectations. I expect JAPAY's share price to outperform peers, driven by strong operating income growth, market share gains, volume growth, and price increases. JAPAY boasts a record-high dividend yield, robust cash flows, and a low-leverage balance sheet, supporting ongoing dividend growth and defensive positioning.
The U.S. Food and Drug Administration proposed a rule on Friday that would require foreign tobacco product makers to register their facilities and list products sold in the country.
Japan Tobacco offers a defensive, income-oriented investment with a 4% yield and strong dividend growth, rated 'Buy'. JAPAY's earnings are projected to grow ~10% annually, driven by expansion in heated tobacco sticks (HTS) and global RRP market share gains. The balance sheet remains robust with $5.5 billion in cash, 50% debt/equity, and a 70% payout ratio supporting consistent dividend increases.
Japan Tobacco Inc. (JAPAY) Q1 2026 Earnings Call Transcript
Six tobacco companies were evaluated using a relative favorability matrix with factors including dividend yield, payout ratio, value, growth, profitability, and leverage. Altria leads the pack with the highest forward yield, low payout ratio, attractive valuation, highest free cash flow margin, and low leverage. Philip Morris and Universal Corporation lag the field with unfavorable payout ratios, weaker margins, and higher leverage.